�Telik, Inc.
(Nasdaq: TELK) announced that its novel small molecule proteasome
inhibitor program met a preclinical development milepost by demonstrating
anticancer activity in preclinical models of human leukemia. The proteasome
is an important cellular structure necessary for the growth and function of
cancer cells and suppression of the
(
Read more... )